We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

zaterdag 24 februari 2018

The Lancet: [Articles] Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, d...

[Articles] Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
The primary endpoint of disease-free survival was not met in cohort 2, and therefore the analysis of cohort 1 showing a numerical benefit in disease-free survival with vemurafenib versus placebo in patients with resected stage IIC�CIIIA�CIIIB BRAFV600 mutation-positive melanoma must be considered exploratory only. 1 year of adjuvant vemurafenib was well tolerated, but might not be an optimal treatment regimen in this patient population.
Read more

[Comment] The brim of uncertainty in adjuvant treatment of melanoma
Until recently, standard options for adjuvant melanoma therapy have been limited to interferon-α and ipilimumab, both of which are associated with substantial toxicity and only modest clinical benefit.1�C3 2017 was a major year for the adjuvant treatment of melanoma as two new regimens were shown to significantly lower the risk of recurrence in patients with resected, high-risk melanoma. The anti-programmed death 1 agent, nivolumab (compared with ipilimumab in the Checkmate 238 study4) and the combination of the RAF and MEK inhibitors, dabrafenib and trametinib (compared with placebo in the COMBI-AD study5) were both shown to improve disease-free survival.
Read more

[News] Possible X chromosome-linked transmission of ovarian cancer
A family history of ovarian cancer is the most reliable predictor of a woman developing the disease, but current genetic models do not explain why the sisters of a woman diagnosed with ovarian cancer have a higher risk of developing the disease than their mother. Findings from a new study suggest an X chromosome-linked pattern of inheritance for ovarian cancer from fathers to daughters.
Read more

[News] Ultra-processed foods might increase cancer risk
The consumption of ultra-processed foods might be proportionally linked to an increased cancer risk, according to results from the ongoing NutriNet-Santé cohort study.
Read more

[Comment] Adjuvant aromatase inhibition: more options for patients
Aromatase inhibitors are the preferred treatment for postmenopausal patients with hormone receptor-positive early breast cancer.1 Third-generation aromatase inhibitors exist in two classes with different modes of action: reversible binding of the aromatase enzyme by the non-steroidal aromatase inhibitors anastrazole and letrozole, and irreversible inhibition of the enzyme by the steroidal aromatase inhibitor exemestane.
Read more